MPM BioImpact Appoints Frank Neumann, M.D., Ph.D., Distinguished Expert in Clinical Development, as Entrepreneur Partner
MPM BioImpact Appoints Frank Neumann, M.D., Ph.D., Distinguished Expert in Clinical Development, as Entrepreneur Partner
BOSTON, April 11, 2024 /PRNewswire/ -- MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver transformative therapies to patients, today announced that Frank Neumann, M.D., Ph.D., will join the Company as Entrepreneur Partner. In addition, Dr. Neumann will join MPM BioImpact portfolio company Orna Therapeutics as Chief Medical Officer.
波士顿,2024年4月11日 /PRNewswire/ — 创建和投资寻求为患者提供变革性疗法的创新公司的生物技术投资公司MPM BioImpact今天宣布,医学博士弗兰克·诺伊曼博士将以企业家合伙人的身份加入该公司。此外,诺伊曼博士将加入MPM BioImpact投资组合公司Orna Therapeutics担任首席医学官。
"Frank is an innovator and distinguished leader with a demonstrated history of success in CAR-based cell therapy and clinical advancement," said Ansbert Gadicke, M.D., Managing Partner of MPM BioImpact. "His extensive experience advancing novel cell therapies and modalities will be valuable as we continue to broaden our investment initiatives and partnerships, building companies to transform patient outcomes."
MPM BioImpact管理合伙人安斯伯特·加迪克医学博士表示:“弗兰克是一位创新者和杰出领导者,在基于汽车的细胞疗法和临床进展方面有着良好的成功历史。”“随着我们继续扩大投资计划和合作伙伴关系,建立公司以改变患者预后,他在推进新型细胞疗法和模式方面的丰富经验将非常宝贵。”
MPM BioImpact Entrepreneur Partners are investor-operators who provide deep domain expertise in research and development, clinical strategy, intellectual property and commercialization, working with the firm's diverse team of scientists and investment professionals to develop therapies for diseases with high unmet needs. Dr. Neumann's deep clinical experience will serve to support MPM BioImpact's investment process and the advancement of its underlying portfolio companies.
MPM BioImpact Entrepreneur Partners是投资者兼运营商,他们在研发、临床战略、知识产权和商业化方面提供深厚的专业知识,与公司的多元化科学家和投资专业人员团队合作,为需求未得到满足的疾病开发疗法。诺伊曼博士的深厚临床经验将为MPM BioImpact的投资流程及其标的投资组合公司的发展提供支持。
"I'm thrilled to join the MPM BioImpact ecosystem and contribute to its patient-focused mission," said Dr. Neumann. "The firm's scientific rigor and expertise in creating companies from the ground up has catalyzed the development of life-saving drugs. This is a very exciting opportunity to help pioneer novel, impactful therapies for patients in need."
诺伊曼博士说:“我很高兴加入MPM BioImpact生态系统,为其以患者为中心的使命做出贡献。”“该公司在从头开始创建公司方面的严谨科学和专业知识催化了救生药物的开发。这是一个非常激动人心的机会,可以帮助有需要的患者开拓新颖的、有影响力的疗法。”
Dr. Neumann currently serves as Senior Vice President and Global Head of Clinical Development at Kite, a Gilead Company, and previously held positions as Chief Medical Officer at Verastem, Inc. (also known as Verastem Oncology) and as Vice President, Head of Oncology Clinical Research at bluebird bio. In addition, Dr. Neumann served as clinical development head for all of Takeda Pharmaceuticals cell therapy approaches globally, and held various leadership roles of increasing prominence, including global clinical lead and medical team lead for two distinct cancer therapies. Earlier in his career, he was a member of the oncology medical teams at AstraZeneca and Sanofi-Aventis.
诺伊曼博士目前在吉利德旗下公司Kite担任高级副总裁兼全球临床开发主管,此前曾在Verastem, Inc.(也称为Verastem Oncology)担任首席医学官和蓝鸟生物副总裁兼肿瘤学临床研究主管。此外,诺伊曼博士曾担任武田制药全球所有细胞疗法的临床开发主管,并担任过越来越重要的各种领导职务,包括两种不同癌症疗法的全球临床负责人和医疗团队负责人。在他职业生涯的早期,他是阿斯利康和赛诺菲安万特肿瘤医疗团队的成员。
In addition to his extensive industry experience, Dr. Neumann is board certified in Hematology/Oncology, Internal Medicine and Palliative Care Medicine. He was a research scholar at the University of Texas MD Anderson Cancer Center and is currently an assistant professor at the Heinrich Heine University in Düsseldorf, Germany. He earned his M.D. from the Heinrich Heine University and his Ph.D. from the Rheinische-Friedrich-Wilhelm University in Bonn, Germany.
除了丰富的行业经验外,诺伊曼博士还获得了血液学/肿瘤学、内科和姑息治疗医学的董事会认证。他曾是德克萨斯大学医学博士安德森癌症中心的研究学者,目前是德国杜塞尔多夫海因里希·海涅大学的助理教授。他在海因里希·海涅大学获得医学博士学位,在德国波恩的莱茵-弗里德里希-威廉大学获得博士学位。
About MPM BioImpact
MPM BioImpact is a world-leading biotechnology investment firm with over 30 years of expertise creating and investing in innovative companies to deliver transformative therapies to patients. Its experienced and dedicated team of investment professionals, entrepreneurs, advisors and leading scientists translate scientific discoveries into breakthrough medicines and potential cures. For more information, visit
关于 MPM BioImpact
MPM BioImpact是一家世界领先的生物技术投资公司,拥有超过30年的专业知识,致力于创建和投资创新公司,为患者提供变革性疗法。其由投资专业人士、企业家、顾问和顶尖科学家组成的经验丰富、敬业的团队将科学发现转化为突破性药物和潜在的治疗方法。欲了解更多信息,请访问
SOURCE MPM BioImpact
来源 MPM BioImpact